focus -WSS

focus

author：fashion 2025-09-27 15:19:42 - browse：7575

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Biden’s NIH nominee is languishing in Congress

hotspot

WSS

Biden to sign 'historic' executive order on how US military handles sexual assault cases

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Wisconsin governor employs partial veto to fund schools for 4 centuries

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

The U.S. needs a new definition of substance use “recovery”

Timeline: Special counsel's probe into Trump's handling of classified documents

entertainment

focus

focus

As demand for Covid shots wanes, Moderna seeks its next success

Biden’s NIH nominee is languishing in Congress

Medicare details structure of new drug price negotiation program

Will biotech layoffs continue through 2023?

Sports medicine is finally prioritizing gender equality

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Psychedelics group wrestles with new pharma identity

Marc Tessier

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Interest rates are at a 22

entertainment

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Teachers share how revamped forgiveness program helped with their student loans

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Biden declares emergency in flood

Create a giant ice tray with this foil pan hack to keep food cold this summer

leisure time

hotspot

explore

Wikipedia